<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">
Log In

SmartTRAK Life Sciences News and Analysis Blog

Kris Jacques

GM, Spine - 30+ years' of diversified global strategic planning, marketing, product development and business development experience. Leadership roles with Alphatec Spine, Vivex Biologics, Smith & Nephew and multiple divisions of General Electric

Recent Posts

2 min read

Trends to Watch in 2025: Interventional Technologies Disrupting the Treatment of CLBP

By Kris Jacques on 4/29/25 9:30 AM

SmartTRAK discusses the latest technologies disrupting the standard of care for chronic low back pain (CLBP)

Non-surgical and less invasive treatment options for CLBP continue to evolve, closing the gap between conservative management and surgical intervention. SmartTRAK estimates that over 450K surgical procedures were performed for low back pain in the US in 2024. However, the number of patients suffering from CLBP is far more significant, and we estimate that over 11 million patients can be treated with new, non-surgical and less invasive technologies.

The treatment approach for spinal back pain starts with conservative measures and progresses to more invasive treatments, depending on the severity and nature of the pain. Treating patients earlier in the cascade can delay the progression and reduce the need for more costly care.
 
In this downloadable article, SmartTRAK discusses the companies and technologies advancing earlier intervention with the potential for disrupting the standard of care cascade, including non-surgical Intradiscal therapeutics and MIS restorative therapies. The article also covers the ongoing shift from spine surgeons to interventionists and the increasingly prominent role of interventional pain physicians. 
 
Click the button below to read the complete Market Outlook article "Trends to Watch in 2025: Interventional Technologies Disrupting the Treatment of CLBP" by Kris Jacques, SmartTRAK  Sr Analyst, Spine and Intradiscal Therapeutics.Get the Article
Topics: Spine
Continue Reading
3 min read

SentryX: Implantable Anesthetic for Spine Surgery

By Kris Jacques on 4/22/25 9:30 AM

SmartTRAK spotlights SentryX, a clinical-stage biopharmaceutical company developing a non-opioid platform for the treatment of acute pain after surgery,​ in an interview at AAOS 2025 in San Diego. 

SentryX Co-Founder and Chief Medical Officer Jorrit-Jan (JJ) Verlaan, MD, discusses the company’s novel implantable anesthetic for spine surgery applications in an interview with SmartTRAK at the American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual meeting in San Diego. The hydrogel works with all types of small-molecule drugs with a release profile that can be tailored to specific clinical needs and surgical procedures.

To find out more about SentryX and its novel technology, listen to the following video. (13:37 min.) A link to download a transcript of the interview is also provided below.


Hi, I’m Kristine Jacques, a Senior Analyst with SmartTRAK Spine. We are here at the American Academy of Orthopedic Surgeons 2025. I’m sitting down with Dr. JJ Verlaan, a spine surgeon, co-founder, and Chief Medical Officer for SentryX, a Netherlands-based company developing a groundbreaking non-opioid solution for postoperative pain. First of all, Dr. Verlaan, I want to congratulate you on being one of the top four finalists inthe OrthoPitch Event at the Academy this year. It’s quite an honor.

Dr. Jorrit-Jan Verlaan: Thank you very much.

Thank you so much for sitting down with the SmartTRAK team. I’d like to start out with you telling us about your background and how the idea came about for the Hydrogel and starting SentryX.

JJV: Thank you so much. I'm a surgeon from Utrecht in the Netherlands. I've been practicing spine surgery from the moment I got board-certified. Rapidly, during work in my practice, I noticed that patients after spine surgery are all in a lot of pain. The moment that you realize that, and you actually ask the patients how much pain they have, on a scale of 0-10 they sometimes respond with a 12. I had a chat with an anesthesiologist one day in between surgeries. We were discussing what is out there right now to treat pain. The anesthesiologist, she told me, "Well, not much, really. We're still relying on opioids. Maybe we could do something with local anesthetics, but it's not working long enough at this point." That kind of sparked the idea of doing something locally to treat the pain, but differently. Soon after, I hit upon the idea that we're developing right now in the company.

How far along are you in the development?

JJV: We started in 2017, together with my partner Bas Oosterman who is the CEO of the company. First it was just a raw idea. We soon found out that this idea, it had never been done before. That gave us the opportunity to actually file IP on our solution and go for it. At the end of 2017  we officially founded the company. We got our first employees and collaborated with a renowned institute on biofabrication. We developed a new ...

Click the button below to download and read the complete transcript of SmartTRAK's interview with SentryX Co-Founder and CMO Jorrit-Jan (JJ) Verlaan, MD, conducted by Kris Jacques, SmartTRAK Sr Analyst.Download the Transcript

Topics: Spine
Continue Reading
3 min read

ISASS: Approaching 25 Years of Advancing Techniques and Technologies for Treating Spinal Disorders

By Kris Jacques on 5/14/24 9:00 AM

ISASS’s Morgan Lorio, MD, president-elect, discusses the obstacles to adopting emerging technologies in spine surgery and the importance of advocating for policy changes to support innovative treatments and improve patient outcomes in an interview with SmartTRAK.

SmartTRAK recently interviewed Morgan Lorio, MD, the incoming president of the International Society for the Advancement of Spine Surgery (ISASS), to learn more about the society’s commitment and goals to spine advocacy and research as it approaches its 25th anniversary as a society.

Key topics discussed include ISASS’s successful efforts in addressing coding and reimbursement challenges to ensure access to innovative treatments for patients, the potential impact of artificial intelligence (AI) on reimbursement, the new ICD-10 codes for discogenic pain, regenerative spine treatments, future directions and initiatives for ISASS and fostering collaboration between industry stakeholders and surgeon societies.

Continue Reading
3 min read

Spine Market Movers to Watch in 2024

By Kris Jacques on 4/9/24 9:30 AM

SmartTRAK highlights companies to watch as they continue their double-digit growth train with multiple catalysts for expansion in 2024.

Overall, the US Spine Market had a remarkable year in 2023 with the completion of the Globus/NuVasive (GMED) merger creating a new #2 in Spine, displacing the incumbent DePuy Synthes (JNJ). SmartTRAK estimates the US Spine Hardware Market grew ~5.5% in 2023. However, many pure-play spine companies exceeded industry growth with exceptional, double-digit growth rates in 2023, while others approached the $100MM revenue milestone. In this article, SmartTRAK highlights five pure-play spine companies to watch and the catalysts driving their expansion in 2024.
 

Continued Double-Digit Growth in 2024

SmartTRAK  expects three spine companies to see continued double-digit growth in 2024, particularly based on competitive moats developing and the ability to execute in their respective purviews, They are:
  • Alphatec Spine: Expanding Its Competitive Moat in Lateral Procedures
    • Alphatec has grown double digits yearly over the last five years. ATEC is now the #1 pure-play Spine Market leader and #5 in the overall Spine Market. These market share gains can be attributed to ... (read more)
  • SI-Bone: Competition Will Test the SI Fusion Market Leader in 2024
    • SI-Bone has grown double digits over the past three years. SIBN is the market leader in minimally invasive spine (MIS) SI Fusion with over 55% market share in the SI Fusion Market and more than ... (read more)
  • Centinel Spine: Fastest Growing Spine Company in 2023
    • In 2023, Centinel Spine was the fastest-growing spine company in one of the fastest-growing areas in spine, motion preservation. Centinel Spine reported record worldwide total disc replacement (TDR) revenue of nearly ... (read more)

Companies Closing in on $100MM in 2024

Both Spinal Elements and Xtant Medical came close to reaching the $100MM revenue mark in 2023 and SmartTRAK expects both to reach that lofty milestone in 2024. 

  • Spinal Elements: Focus on MIS Innovation, the Aging Spine and ASCs
    • Spinal Elements was just shy of $100MM in revenues in 2023. The company is focused on some of the fastest-growing trends in spine including ... (read more)
  • Xtant Medical:  Integrated Hardware, Biologics and More Acquisitions
    • Xtant Medical (XTNT) is also closing in on the $100MM revenue mark, growing +54.5% over 2022. XTNT had an exciting year of acquisition activity, including ... (read more)

To download the complete "Spine Market Movers to Watch in 2024" article by SmartTRAK's  Kris Jacques, please just click the button below. Read the Article

Continue Reading
2 min read

Trends, Advancing Technologies and New Deals Shaping the Future of Spine: NASS 2023

By Kris Jacques on 12/5/23 9:45 AM

SmartTRAK was on-site at NASS 2023 covering the latest spine trends including hosting the hottest reception in town, “Targeting the ASC, What Spine Companies Need to Know."

Shifting hospital-based procedures to the ambulatory surgery center (ASC) is one of the biggest opportunities for healthcare savings and the opportunity is especially great for spine given its high acuity procedures like lateral lumbar fusions, 360 fusions and total disc replacements (TDRs) according to the results of SmartTRAK’s recent survey of 30 ortho, spine and neurosurgeons. At this year’s North American Society (NASS) Annual Meeting held in Los Angeles, CA October 18-21, SmartTRAK hosted a standing-room-only reception for industry on the migration of spine procedures into the ASC titled “Targeting the ASC: What Manufacturers Need to Know,” which included panel discussions and presentations focused on the spine market and practice trends. In this article, SmartTRAK highlights the top takeaways from the reception and identifies the latest trends and innovations at NASS affecting growth in the US Spine Market. Topics covered in the article include:

  • New Care Models Optimizing Outpatient Spine
  • The Motion Preservation “Renaissance” was Hard to Miss
  • MIS SI Joint Fusion Systems – A Plethora of Systems, New Devices Launching Ahead of 2024 Reimbursement Changes.
  • Will New Interbody Technologies Displace the Need for Biologics?
  • Deals Abound: Several Biologics Deals Announced at NASS and After

To download and read the complete "NASS 2023: Trends, Advancing Technologies and New Deals Shaping the Future of Spine" article by Kris Jacques,  SmartTRAK's GM, Spine, just click the button below. Read the Article

Topics: Spine
Continue Reading
2 min read

US MIS SI Joint Fusion Market: Unlocking the Future of Spine

By Kris Jacques on 11/28/23 9:49 AM

Ready to dive into one of the most rapidly expanding markets in the world of Spine? Welcome to the realm of SI Joint Fusion, a market poised for remarkable growth with a projected 5-year CAGR of +18%. At SmartTRAK, we’re excited to introduce you to this thriving sector and give you a sneak peek of our forthcoming in-depth market segment solution subscription.

Outlined below is a brief list highlighting some of the key insights awaiting you upon subscribing to SmartTRAK's innovative solution and the valuable knowledge it delivers:

  • Market Overview (US only/MIS market only):
    - Incidence and Prevalence: Understand the scale of SI Joint Fusion cases.
    - Market Size: Explore the market's current size and potential.
    - Revenue/Procedure Forecast through 2027: Take a look at expected future growth by market segments; transfixing and non-transfixing.
    - Growth Trends: Stay ahead with insights into emerging trends.
  • Competitive Landscape:
    - By System Type: Discover the differences between Transfixing and Non-transfixing.
    - 2022 ASP Data Summary: Gain access to crucial pricing information.
  • National/Regional Site of Service Procedure Volume Data:
    - HOPD vs ASC vs. Inpatient: Know where these procedures are performed.     - Annual Trends from 2017: Track the historical data for insights. 
  • Coding & Reimbursement - 2024 Outlook:
    - Anticipate changes in coding and reimbursement for the coming year.
  • Why MIS SIJ Fusion Matters:
    Within the vast Spine landscape, the Minimally Invasive Surgery (MIS) SI Joint Fusion procedure category is the star of the show. Here's why:
    - Growing Awareness and Diagnosis: More individuals are recognizing SI joint pain as a significant issue.
    - Robust Clinical Data: The body of clinical evidence is expanding.
    - Increasing Reimbursement Coding: Hospitals, HOPDs, ASCs and Physician's offices.
  • The Future of MIS SI Joint Fusion:
    Acceptance of the posterior/dorsal non-transfixing MIS SI fusion approach is on the rise. This process is set to drive procedural growth and popularity, particularly among interventional pain physicians at Ambulatory Surgical Centers (ASCs).

So are you ready to dive into one of the most rapidly expanding markets in the world of Spine? Don’t miss your chance to stay ahead of the curve in the booming world of SI Joint Fusion and Be The Expert! Just click the button below to find out more. Be The Expert!

Topics: Top Story Spine
Continue Reading
2 min read

Advancing Cutting Edge Alternatives to Fusion: ISASS 2023

By Kris Jacques on 7/4/23 9:30 AM

SmartTRAK highlights cutting-edge advances in non-fusion technologies and motion-preserving treatments presented at ISASS 2023.

SmartTRAK highlights the latest news, research and advancements in non-fusion technologies and motion-preserving treatments presented at the International Society for the Advancement of Spine Surgery (ISASS 2023) 23rd Annual Conference held in San Francisco, CA in June. Companies have been developing non-fusion technologies for decades. Based on the scientific program presentations, it’s evident that many are getting closer to US commercialization supported by clinical evidence and design optimizations.

Among the many topics covered in this fascinating and informative article are:

  • Facet Replacement: “The Transition Zone”
  • Nucleus Replacement: Lessons from 30 Years of History
  • Intradiscal Cell Therapy: The Holy Grail?
  • Preventing Lumbar Disc Reherniation and Reducing the Economic Burden

These technologies address the limitations with spinal fusion surgery for lumbar degenerative disc disease (DDD), spondylolisthesis and stenosis. Lower back pain (LBP) associated with these pathologies has a substantial economic impact, being the most common cause of disability worldwide, constituting the second leading cause of ...

To download and read the complete "ISASS 2023: Advancing Cutting Edge Alternatives to Fusion" just click the button below. Download the Article

Topics: Spine
Continue Reading
  • There are no suggestions because the search field is empty.

Recent Articles